tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Murase N et al. | FK 506 prevents spontaneous diabetes in the BB rat. | 1991 | Transplant. Proc. | pmid:1703705 |
| Meiser BM et al. | Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. | 1991 | Lancet | pmid:1719321 |
| Watanabe K et al. | Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. | 1991 | Transplant. Proc. | pmid:1703706 |
| Jorgensen WL | Rusting of the lock and key model for protein-ligand binding. | 1991 | Science | pmid:1719636 |
| Kobayashi N et al. | Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. | 1991 | Transplant. Proc. | pmid:1703707 |
| Keenan RJ et al. | Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. | 1991 | Transplantation | pmid:1719668 |
| Strasser S et al. | The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. | 1991 | Transplant. Proc. | pmid:1703709 |
| Ali Shah I et al. | Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. | 1991 | Transplant. Proc. | pmid:1721276 |
| Moochhala SM et al. | Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721277 |
| Sumpio BE and Phan S | Nephrotoxic potential of FK 506. | 1991 | Transplant. Proc. | pmid:1721278 |
| Pichard L et al. | Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. | 1991 | Transplant. Proc. | pmid:1721279 |
| Katz HR et al. | Mast cell biochemical and functional heterogeneity. | 1991 | Transplant. Proc. | pmid:1721308 |
| de Paulis A et al. | Antiinflammatory effect of FK 506 on human basophils. | 1991 | Transplant. Proc. | pmid:1721309 |
| Su MS and Semerjian A | Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. | 1991 | Transplant. Proc. | pmid:1721310 |
| Andersson J et al. | The effects of FK 506 on cytokine production are dependent on the mode of cell activation. | 1991 | Transplant. Proc. | pmid:1721311 |
| Rucay P et al. | FK 506 rescue therapy for refractory acute rejection in five liver recipients. | 1991 | Transplant. Proc. | pmid:1721340 |
| Macleod AM and Thomson AW | FK 506: an immunosuppressant for the 1990s? | 1991 | Lancet | pmid:1702172 |
| Reding R et al. | Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. | 1991 | Transplant. Proc. | pmid:1721341 |
| Uemoto S et al. | Experience with FK 506 in living related donor liver transplantation. | 1991 | Transplant. Proc. | pmid:1721342 |
| Tzakis AG et al. | FK 506 versus cyclosporine in pediatric liver transplantation. | 1991 | Transplant. Proc. | pmid:1721343 |
| Fung JJ et al. | Adverse effects associated with the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721372 |
| Omar G et al. | FK 506 inhibition of cyclosporine metabolism by human liver microsomes. | 1991 | Transplant. Proc. | pmid:1703356 |
| Hebert MF et al. | Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721373 |
| Eiras G et al. | Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. | 1991 | Transplant. Proc. | pmid:1703357 |
| Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721374 | |
| Christians U et al. | Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. | 1991 | Transplant. Proc. | pmid:1703358 |
| Morris SM et al. | Disruption of renal function and gene expression by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721375 |
| Lagodziński Z et al. | Effect of FK 506 on B-cell responses. | 1991 | Transplant. Proc. | pmid:1703359 |
| Jacobs TW et al. | The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. | 1991 | Transplant. Proc. | pmid:1721403 |
| Abu-Elmagd KM et al. | Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721404 |
| Adams CK and Famili P | A study of the effects of the drug FK 506 on gingival tissues. | 1991 | Transplant. Proc. | pmid:1721405 |
| Steinmann B et al. | Mechanism of action of FK 506 and cyclosporin. | 1991 | Lancet | pmid:1704088 |
| Sewing KF and Christians U | FK 506. | 1991 | Lancet | pmid:1704090 |
| Wiederrecht G et al. | FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1704127 |
| Wada H et al. | An attempt to induce tolerance to skin grafts in congenic mice with FK 506. | 1991 | Transplant. Proc. | pmid:1721435 |
| Kuroki H et al. | Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. | 1991 | Transplant. Proc. | pmid:1721436 |
| Ito T et al. | Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. | 1991 | Transplant. Proc. | pmid:1721437 |
| DeValeria PA et al. | FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. | 1991 | Transplant. Proc. | pmid:1721438 |
| Neuberger J | FK 506--a promise of good things to come? | 1991 | Hepatology | pmid:1711005 |
| Halloran PF and Madrenas J | The mechanism of action of cyclosporine: a perspective for the 90's. | 1991 | Clin. Biochem. | pmid:1711939 |
| Palaszynski EW et al. | Purification and characterization of cyclosporine and FK-506 binding proteins from a human T-helper cell line. | 1991 | Clin. Biochem. | pmid:1711940 |
| Shiraki K et al. | Effect of FK-506 on replication of human cytomegalovirus in vitro. | 1991 | J. Antibiot. | pmid:1712008 |
| Morris PJ | Cyclosporine, FK-506 and other drugs in organ transplantation. | 1991 | Curr. Opin. Immunol. | pmid:1721824 |
| Lhoëst G et al. | Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. | 1991 | Pharm Acta Helv | pmid:1722046 |
| Nicoletti F et al. | FK-506 prevents diabetes in diabetes-prone BB/Wor rats. | 1991 | Int. J. Immunopharmacol. | pmid:1722192 |
| Starzl TE et al. | [Clinical experience with FK 506]. | 1991 | Presse Med | pmid:1722311 |
| Brizuela L et al. | Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. | 1991 | Mol. Cell. Biol. | pmid:1715022 |
| Heitman J et al. | Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. | 1991 | Science | pmid:1715094 |
| Morris RE | Rapamycin: FK506's fraternal twin or distant cousin? | 1991 | Immunol. Today | pmid:1715165 |
| Baumann G et al. | Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. | 1991 | New Biol. | pmid:1715185 |